SCHEMBL1946253

SCHEMBL1946253

CSCCC(O)C(O)C(N)c1c[nH]c2c(=O)[nH]c(N)nc12

nearest known ligand 0.47

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PNP P00491 16/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1946850 0.86 PNP (0.56) PNP
SCHEMBL1948919 0.82 PNP (0.48) PNP
SCHEMBL1223296 0.81 MTAP (0.35)
SCHEMBL1946202 0.77 PNP (0.44) PNP
SCHEMBL1222678 0.76 MTAP (0.52)
SCHEMBL1947944 0.73 PNP (0.57) PNP
SCHEMBL1946278 0.72 PNP (0.58) PNP
SCHEMBL22907452 0.72 PNP (0.56) PNP
SCHEMBL9282984 0.71 PNP (0.49) PNP
SCHEMBL1945348 0.70 MTAP (0.62) PNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853224-B2 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases INDUSTRIAL RESEARCH LIMITED (NZ) 2014-10-07 US claimed
WO-2012074912-A1 METHODS, ASSAYS AND COMPOUNDS FOR TREATING BACTERIAL INFECTIONS BY INHIBITING METHYLTHIOINOSINE PHOSPHORYLASE ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2012-06-07 WO claimed
US-20110130412-A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases BIOCRYST PHARMACEUTICALS, INC. 2011-06-02 US claimed
WO-2009082247-A1 PROCESS FOR PREPARING IMMUCILLINS HAVING A METHYLENE LINK INDUSTRIAL RESEARCH LIMITED (NZ) 2009-07-02 WO claimed
US-10918641-B2 Use of MTAP inhibitors for the treatment of lung disease THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2021-02-16 US disclosed
US-20180353511-A1 Use of MTAP Inhibitors for the Treatment of Lung Disease ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. 2018-12-13 US disclosed
US-9290501-B2 Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) 2016-03-22 US disclosed
US-8853224-B2 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases INDUSTRIAL RESEARCH LIMITED (NZ) 2014-10-07 US disclosed
US-20130274220-A1 METHODS, ASSAYS AND COMPOUNDS FOR TREATING BACTERIAL INFECTIONS BY INHIBITING METHYLTHIOINOSINE PHOSPHORYLASE INDUSTRIAL RESEARCH LIMITED (NZ) 2013-10-17 US disclosed
WO-2012074912-A1 METHODS, ASSAYS AND COMPOUNDS FOR TREATING BACTERIAL INFECTIONS BY INHIBITING METHYLTHIOINOSINE PHOSPHORYLASE ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2012-06-07 WO disclosed
EP-2395005-A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases Industrial Research Limited (NZ) 2011-12-14 EP disclosed
US-20110130412-A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases BIOCRYST PHARMACEUTICALS, INC. 2011-06-02 US disclosed
WO-2009082247-A1 PROCESS FOR PREPARING IMMUCILLINS HAVING A METHYLENE LINK INDUSTRIAL RESEARCH LIMITED (NZ) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180353511-A1 Use of MTAP Inhibitors for the Treatment of Lung Disease MTAP, TYMP, TPMT PNP 5/4885
US-20110130412-A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases PNP, TYMP, NTPCR PNP 1/4885
US-10918641-B2 Use of MTAP inhibitors for the treatment of lung disease MTAP, TYMP, TPMT PNP 5/4885
US-20130274220-A1 METHODS, ASSAYS AND COMPOUNDS FOR TREATING BACTERIAL INFECTIONS BY INHIBITING METHYLTHIOINOSINE PHOSPHORYLASE MTAP, MPG, MTMR1 PNP 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.